- Home
- LWAC vs DMAC Comparison
LWAC vs DMAC Comparison
Compare LWAC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAC
- DMAC
- Stock Information
- Founded
- LWAC 2025
- DMAC 2000
- Country
- LWAC United States
- DMAC United States
- Employees
- LWAC N/A
- DMAC N/A
- Industry
- LWAC
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LWAC
- DMAC Health Care
- Exchange
- LWAC Nasdaq
- DMAC Nasdaq
- Market Cap
- LWAC 303.5M
- DMAC 321.5M
- IPO Year
- LWAC 2025
- DMAC N/A
- Fundamental
- Price
- LWAC $10.09
- DMAC $6.91
- Analyst Decision
- LWAC
- DMAC Strong Buy
- Analyst Count
- LWAC 0
- DMAC 4
- Target Price
- LWAC N/A
- DMAC $15.50
- AVG Volume (30 Days)
- LWAC 93.4K
- DMAC 371.1K
- Earning Date
- LWAC 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- LWAC N/A
- DMAC N/A
- EPS Growth
- LWAC N/A
- DMAC N/A
- EPS
- LWAC N/A
- DMAC N/A
- Revenue
- LWAC N/A
- DMAC N/A
- Revenue This Year
- LWAC N/A
- DMAC N/A
- Revenue Next Year
- LWAC N/A
- DMAC N/A
- P/E Ratio
- LWAC N/A
- DMAC N/A
- Revenue Growth
- LWAC N/A
- DMAC N/A
- 52 Week Low
- LWAC $9.81
- DMAC $3.19
- 52 Week High
- LWAC $10.14
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- LWAC N/A
- DMAC 55.80
- Support Level
- LWAC N/A
- DMAC $5.26
- Resistance Level
- LWAC N/A
- DMAC $6.47
- Average True Range (ATR)
- LWAC 0.00
- DMAC 0.51
- MACD
- LWAC 0.00
- DMAC 0.00
- Stochastic Oscillator
- LWAC 0.00
- DMAC 86.55
About LWAC LightWave Acquisition Corp. Class A Ordinary Shares
LightWave Acquisition Corp is a blank check company.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.